Muhammad Zahid Khan1, Ling He2. 1. Department of Pharmacology, China Pharmaceutical University, No. 24 Tong Jia Xiang, Nanjing, Jiangsu Province, 210009, China. mzahidk786@hotmail.com. 2. Department of Pharmacology, China Pharmaceutical University, No. 24 Tong Jia Xiang, Nanjing, Jiangsu Province, 210009, China.
Abstract
BACKGROUND: In the central nervous system (CNS), G protein-coupled receptors (GPCRs) are the most fruitful targets for neuropsychopharmacological drug development. Rhodopsin (class A) is the most studied class of GPCR and includes orphan receptors for which the endogenous ligand is not known or is unclear. Characterization of orphan GPCRs has proven to be challenging, and the production pace of GPCR-based drugs has been incredibly slow. OBJECTIVE: Determination of the functions of these receptors may provide unexpected insight into physiological and neuropathological processes. Advances in various methods and techniques to investigate orphan receptors including in situ hybridization and knockdown/knockout (KD/KO) showed extensive expression of these receptors in the mammalian brain and unmasked their physiological and neuropathological roles. Due to these rapid progress and development, orphan GPCRs are rising as a new and promising class of drug targets for neurodegenerative diseases and psychiatric disorders. CONCLUSION: This review presents a neuropsychopharmacological perspective of 26 orphan receptors of rhodopsin (class A) family, namely GPR3, GPR6, GPR12, GPR17, GPR26, GPR35, GPR39, GPR48, GPR49, GPR50, GPR52, GPR55, GPR61, GPR62, GPR63, GPR68, GPR75, GPR78, GPR83, GPR84, GPR85, GPR88, GPR153, GPR162, GPR171, and TAAR6. We discussed the expression of these receptors in mammalian brain and their physiological roles. Furthermore, we have briefly highlighted their roles in neurodegenerative diseases and psychiatric disorders including Alzheimer's disease, Parkinson's disease, neuroinflammation, inflammatory pain, bipolar and schizophrenic disorders, epilepsy, anxiety, and depression.
BACKGROUND: In the central nervous system (CNS), G protein-coupled receptors (GPCRs) are the most fruitful targets for neuropsychopharmacological drug development. Rhodopsin (class A) is the most studied class of GPCR and includes orphan receptors for which the endogenous ligand is not known or is unclear. Characterization of orphan GPCRs has proven to be challenging, and the production pace of GPCR-based drugs has been incredibly slow. OBJECTIVE: Determination of the functions of these receptors may provide unexpected insight into physiological and neuropathological processes. Advances in various methods and techniques to investigate orphan receptors including in situ hybridization and knockdown/knockout (KD/KO) showed extensive expression of these receptors in the mammalian brain and unmasked their physiological and neuropathological roles. Due to these rapid progress and development, orphan GPCRs are rising as a new and promising class of drug targets for neurodegenerative diseases and psychiatric disorders. CONCLUSION: This review presents a neuropsychopharmacological perspective of 26 orphan receptors of rhodopsin (class A) family, namely GPR3, GPR6, GPR12, GPR17, GPR26, GPR35, GPR39, GPR48, GPR49, GPR50, GPR52, GPR55, GPR61, GPR62, GPR63, GPR68, GPR75, GPR78, GPR83, GPR84, GPR85, GPR88, GPR153, GPR162, GPR171, and TAAR6. We discussed the expression of these receptors in mammalian brain and their physiological roles. Furthermore, we have briefly highlighted their roles in neurodegenerative diseases and psychiatric disorders including Alzheimer's disease, Parkinson's disease, neuroinflammation, inflammatory pain, bipolar and schizophrenic disorders, epilepsy, anxiety, and depression.
Authors: Anissa Sidibe; Amandine Mullier; Patty Chen; Marc Baroncini; Jean A Boutin; Philippe Delagrange; Vincent Prevot; Ralf Jockers Journal: J Pineal Res Date: 2010-02-23 Impact factor: 13.007
Authors: Philip E Brandish; Ming Su; Daniel J Holder; Paul Hodor; John Szumiloski; Robert R Kleinhanz; Jaime E Forbes; Mollie E McWhorter; Sven J Duenwald; Mark L Parrish; Sang Na; Yuan Liu; Robert L Phillips; John J Renger; Sethu Sankaranarayanan; Adam J Simon; Edward M Scolnick Journal: Neuron Date: 2005-03-24 Impact factor: 17.173
Authors: Manuel Sanchez-Alavez; Olivia Osborn; Iustin V Tabarean; Kristina H Holmberg; James Eberwine; C Ronald Kahn; Tamas Bartfai Journal: J Biol Chem Date: 2011-02-17 Impact factor: 5.157
Authors: Timothy S Breton; William G B Sampson; Benjamin Clifford; Anyssa M Phaneuf; Ilze Smidt; Tamera True; Andrew R Wilcox; Taylor Lipscomb; Casey Murray; Matthew A DiMaggio Journal: Sci Rep Date: 2021-06-08 Impact factor: 4.379
Authors: Alexander Chamessian; Michael Young; Yawar Qadri; Temugin Berta; Ru-Rong Ji; Thomas Van de Ven Journal: Sci Rep Date: 2018-05-01 Impact factor: 4.379